---
title: "Sanofi faces stock decline as CEO change announced, market cap of $113.6B, shares down 4.5%, near 52-week low."
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275910122.md"
description: "Sanofi SA's shares fell 4.5% in premarket trading following the announcement of CEO Paul Hudson's departure, with a market cap of $113.6 billion. The stock is nearing its 52-week low of $44.62-$60.12. Belén Garijo will succeed Hudson after the Annual General Meeting on April 29. The company aims to enhance its strategy and innovation in R&D, despite ongoing challenges in its drug pipeline. In Q4 2025, sales of Dupixent rose by 32.2% to 4.2 billion euros."
datetime: "2026-02-13T13:29:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275910122.md)
  - [en](https://longbridge.com/en/news/275910122.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275910122.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/275910122.md) | [繁體中文](https://longbridge.com/zh-HK/news/275910122.md)


# Sanofi faces stock decline as CEO change announced, market cap of $113.6B, shares down 4.5%, near 52-week low.

Sanofi SA (NASDAQ: SNY) shares are experiencing a decline in the premarket session on Friday due to leadership changes amidst ongoing issues in its drug pipeline. The French drugmaker, with a market cap of approximately $113.6 billion, closed 4.5% lower on Thursday, moving closer to the lower end of its 52-week range of $44.62-$60.12. The departure of CEO Paul Hudson was announced by the board, with Belén Garijo set to succeed him. Hudson's last day as CEO is scheduled for February 17, and Garijo will assume the role after the Annual General Meeting on April 29. Sanofi aims to strengthen its strategy and innovation capacity, particularly in Research & Development. In the fourth quarter of 2025, Sanofi saw a significant 32.2% increase in sales of its leading drug, Dupixent, amounting to 4.2 billion euros.

### 相关股票

- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md)
- [Sanofi (SNYNF.US)](https://longbridge.com/zh-CN/quote/SNYNF.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [Sanofi (SNY.US)](https://longbridge.com/zh-CN/quote/SNY.US.md)

## 相关资讯与研究

- [How New CHMP Opinions on Dupixent and Acoziborole Will Impact Sanofi (ENXTPA:SAN) Investors](https://longbridge.com/zh-CN/news/278666481.md)
- [XY Capital Ltd Acquires Shares of 33,970 Sanofi $SNY](https://longbridge.com/zh-CN/news/279122080.md)
- [Novo Nordisk’s New Oral Anti-Inflammatory Candidate Clears First Human Study Milestone](https://longbridge.com/zh-CN/news/278754561.md)
- [Novo Nordisk Targets Next-Gen Diabetes Control With New Once‑Weekly Drug Trial](https://longbridge.com/zh-CN/news/278754873.md)
- [Brazil's EMS purchases Sanofi's Medley](https://longbridge.com/zh-CN/news/278113014.md)